Fluorescent Nanoparticles Coated with a Somatostatin Analogue Target Blood Monocyte for Efficient Leukaemia Treatment
- PDF / 1,295,655 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 91 Downloads / 153 Views
RESEARCH PAPER
Fluorescent Nanoparticles Coated with a Somatostatin Analogue Target Blood Monocyte for Efficient Leukaemia Treatment Ahmed A. H. Abdellatif 1,2,3 Achim Goepferich 3
&
Robert Hennig 3 & Klaus Pollinger 3 & Hesham M. Tawfeek 4 & Abdellatif Bouazzaoui 5,6 &
Received: 7 May 2020 / Accepted: 23 September 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
ABSTRACT Background Leukaemia is the most prevalent form of cancer-causing death in a large number of populations and needs prompt and effective treatment. Chemotherapeutics can be used to treat leukaemia, but their pronounced killing effects to other living cells is still an issue. Active targeting to certain specific receptors in leukaemic cells is the best way to avoid damage to other living cells. Leukaemic cells can be targeted using novel nanoparticles (NPs) coated with a specific ligand, such as octreotide (OCD), to target somatostatin receptor type 2 (SSTR2), which is expressed in leukaemic cells. Methods Amino-PEGylated quantum dots (QDs) were chosen as model NPs. The QDs were first succinylated using succinic anhydride and then coated with OCD. The reactivity and selectivity of the formulated QDs-OCD were studied in cell lines with well-expressed SSTR2, while fluorescence was
detected using confocal laser scanning microscopy (CLSM) and flow cytometry (FACS). Conclusively, QD-OCD targeting to blood cells was studied in vivo in mice and detected using inductively coupled plasma mass spectrometry and CLSM in tissues. Results Highly stable QDs coated with OCD were prepared. FACS and CLSM showed highly definite interactions with overexpressed SSTR 2 in the investigated cell lines. Moreover, the in vivo results revealed a higher concentration of QDs-OCD in blood cells. The fluorescence intensity of the QDs-OCD was highly accumulated in blood cells, while the unmodified QDs did not accumulate significantly in blood cells. Conclusion: The formulated novel QDs-OCD can target SSTR2 overexpressed in blood cells with great potential for treating blood cancer.
KEY WORDS fluorescent nanoparticles, leukaemia, active Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11095-020-02938-1) contains supplementary material, which is available to authorized users. * Ahmed A. H. Abdellatif [email protected]; [email protected]
1
Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraydah 51452, Qassim, Kingdom of Saudi Arabia
2
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt
3
Department of Pharmaceutical Technology Department, Faculty of Chemistry and Pharmacy, Regensburg University, 93040 Regensburg, Germany
4
Department of Industrial Pharmacy, Faculty of Pharmacy, Assiut University, 71526 Assiut, Egypt
5
Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, P.O. Box 715, Makkah 21955, Saudi Arabia
6
Science and Technology Unit, Umm Al Qura University, P.O
Data Loading...
